Кабозантиниб при гепатоцеллюлярном раке: от предклинических экспериментов к наблюдательным исследованиям
https://doi.org/10.17650/2686-9594-2022-12-4-41-51
Аннотация
По результатам регистрационных исследований препарат кабозантиниб, механизм действия которого определяется ингибированием тирозинкиназ относительно широкого спектра клеточных рецепторов, зарегистрирован в лечении гепатоцеллюлярного рака, рака почки и рака щитовидной железы. В данном обзоре литературы собраны данные по механизму действия, результаты предклинических экспериментов и исследований I–III фаз. Акцент сделан на особенностях переносимости и эффективности препарата в популяции пациентов с гепатоцеллюлярным раком.
Об авторе
М. Ю. Федянин
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России; ГБУЗ «Московский многопрофильный клинический центр «Коммунарка» Департамента здравоохранения г. Москвы»; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России
Россия
Россия
Михаил Юрьевич Федянин
115478 Москва, Каширское шоссе, 24
108814 Москва, ул. Сосенский стан, 8
105203 Москва, ул. Нижняя Первомайская, 70
Список литературы
1. Xiang Q., Chen W., Ren M. et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res 2014;20(11):2959–70. DOI:10.1158/1078-0432.CCR-13-2620
2. Rimassa L., Abbadessa G., Personeni N. et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget 2016;7(45):72622–33. DOI:10.18632/oncotarget.11621
3. Rimassa L., Assenat E., Peck-Radosavljevic M. et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 2018;19(5):682–93. DOI:10.1016/S1470-2045(18)30146-3
4. Trojan J. Cabozantinib for the treatment of advanced hepatocellular carcinoma: current data and future perspectives. Drugs 2020;80:1203–10. DOI:10.1007/s40265-020-01361-5
5. Abou-Alfa G.K., Meyer T., Cheng A.L. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54–63.
6. Yakes F.M., Chen J., Tan J. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298–308.
7. Matsui J., Yamamoto Y., Funahashi Y. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122(3):664–71.
8. Mishra A., Wang J., Shiozawa Y. et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol Cancer Res 2012;10(6):703–12.
9. Akalu Y.T., Rothlin C.V., Ghosh S. TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev 2017;276(1):165–77.
10. Sennino B., Ishiguro-Oonuma T., Wei Y. et al. Suppression of tumor invasion and metastasis by concurrent inhibition of cMet and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270–87. DOI:10.1158/2159-8290.CD-11-0240
11. Xiang Q., Chen W., Ren M. et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res 2014;20:2959–70. DOI:10.1158/1078-0432.CCR-13-2620
12. Bentzien F., Zuzow M., Heald N. et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013;23:1569–77. DOI:10.1089/thy.2013.0137
13. Ott P.A., Hodi F.S., Buchbinder E.I. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015;5:202. DOI:10.3389/fonc.2015.00202
14. Voron T., Marcheteau E., Pernot S. et al. Control of the immune response by pro-angiogenic factors. Front Oncol 2014;4:70. DOI:10.3389/fonc.2014.00070
15. Guo Z., Li Y., Zhang D., Ma J. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models. Oncotarget 2017;8(52):89761–74.
16. Tripathi M., Nandana S., Billet S. et al. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget 20170;8(50):87891–902.
17. Kwilas A.R., Ardiani A., Donahue R.N. et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immunemediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med 2014;12:294.
18. Holtzhausen A., Harris W., Ubil E. et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunol Res 2019;7(10):1672–86.
19. Graham D.K., DeRyckere D., Davies K.D., Earp H.S. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014;14:769–85. DOI:10.1038/nrc3847
20. Aguilera T.A., Rafat M., Castellini L. et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun 2016;7:13898. DOI:10.1038/ncomms13898
21. Tripathi M., Nandana S., Billet S. et al. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget 2017;8(50):87891–902.
22. Myers K.V., Amend S.R., Pienta K.J. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer 2019;18(1):94.
23. Shang R., Song X., Wang P. al. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut 2020. DOI:10.1136/gutjnl-2020-320716
24. Verzoni E., Ferro S., Procopio G. et al. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts). Ann Oncol 2018;29(Suppl 8):abstr. 882P. DOI:10.1093/annonc/mdy283.091
25. Apolo A.B., Tomita Y., Lee M.-J. et al. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. In Abstract 4501 presented at ASCO Annual Meeting, May 30 – June 3, 2014. DOI:10.1200/jco.2014.32.15_suppl.4501
26. Tolaney S.M., Ziehr D.R., Guo H. et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. Oncologist 2017;22:25–32. DOI:10.1634/theoncologist.2016-0229
27. Agarwal N., Loriot Y., McGregor B.A. et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. In Abstract 5564 and poster 145 presented at ASCO Annual Meeting, May 29 – June 2, 2020. DOI:10.1200/JCO.2020.38.15_suppl.5564
28. Caruso S., Calatayud A.L., Pilet J. et al. Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response. Gastroenterology 2019;157(3):760–76. DOI:10.1053/j.gastro.2019.05.001
29. Kurzrock R., Sherman S.I., Ball D.W. et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660–6. DOI:10.1200/JCO.2010.32.4145
30. Choueiri T.K., Pal S.K., McDermott D.F. et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014;25:1603–8. DOI:10.1093/annonc/mdu184
31. Beuselinck B., Oudard S., Rixe O. et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011;22:794–800.
32. Nguyen H.M., Ruppender N., Zhang X. et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 2013;8:e78881.
33. Dai J. Zhang H. Karatsinides A.et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 2014;20:617–30.
34. Nguyen L., Chapel S., Tran B.D., Lacy S. Cabozantinib exposure– response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. J Pharmacokinet Pharmacodyn. DOI:10.1007/s10928-019-09659-y
35. Lacy S.A., Miles D.R., Nguyen L.T. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet 2017;56:477–91. DOI:10.1007/s40262-016-0461-9
36. Cabometyx (cabozantinib) (package insert). Alameda, CA: Exelixis, Inc.; 2019. Cabometyx Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/productinformation/cabometyx-epar-product-information_en.pdf.
37. Schwartz G., Darling J.O., Mindo M., Damicis L. Management of adverse events associated with cabozantinib treatment in patients with advanced hepatocellular carcinoma. Target Oncol 2020;15:549–65. DOI:10.1007/s11523-020-00736-8
38. Nguyen L., Holland J., Ramies D. et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol 2016;56:1130–40. DOI:10.1002/jcph.714
39. Lacy S., Nielsen J., Yang B. et al. Population exposureresponse analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharmacol 2018;81:1061–70. DOI:10.1007/s00280-018-3579-7
40. Nguyen L., Chapel S., Tran B.D., Lacy S. Updated population pharmacokinetic model of cabozantinib integrating various cancer types including hepatocellular carcinoma. J Clin Pharmacol 2019;59:1551–61. DOI:10.1002/jcph.1467
41. Schoffski P., Gordon M., Smith D.C. et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer 2017;86:296–304. DOI:10.1016/j.ejca.2017.09.011
42. Kelley R.K., Verslype C., Cohn A.L. et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017;28:528–34. DOI:10.1093/annonc/mdw651.
43. Kudo M., Tsuchiya K., Kato N. et al. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 2021;56:181–90.
44. Llovet J.M., Ricci S., Mazzaferro V. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–90. DOI:10.1056/NEJMoa0708857
45. Rimassa L., Cicin I., Blanc J.-F. et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). In Abstract 4090 and poster 279 presented at ASCO Annual Meeting, June 1–5, 2018. DOI:10.1200/JCO.2018.36.15_suppl.409
46. Blanc J.F., Meyer T., Cheng A.-L. et al. Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Abstract 703P presented at ESMO Annual Meeting, October 19–23, 2018. DOI:10.1093/annonc/mdy282.086
47. Yau T., Cheng A.-L., Meyer T. et al. Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC). In Abstract 704P presented at ESMO Annual Meeting, October 19–23, 2018. DOI:10.1093/annonc/mdy282.087
48. Kelley R.K., Ryoo B.Y., Merle P. et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open 2020;5:e000714. DOI:10.1136/esmoopen-2020-000714
49. Miksad R., Cicin I., Chen Y. et al. Outcomes based on AlbuminBilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). In Abstract O-022 presented at ESMO World GI Congress, July 3–6, 2019. DOI:10.1093/annonc/mdz154.021
50. El-Khoueiry A.B., Meyer T., Cheng A.L. et al. Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo. In Abstract O-24 presented at International Liver Cancer Association Virtual Conference, September 11–13, 2020.
51. El-Khoueiry A.B., Meyer T., Cheng A.L. et al. Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo. In Abstract SO-9 presented at ESMO World Congress on Gastrointestinal Cancer, July 1–4, 2020.
52. Abou-Alfa G.K., Mollon P., Meyer T. et al. Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial. J Clin Oncol 2019;37(4 Suppl):207.
53. Delos Santos S., Udayakumar S., Nguyen A. et al. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma. Curr Oncol 2020;27(6)300–6.
54. Rimassa L., Danesi R., Pressiani T., Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20–8.
55. Finkelmeiera F., Scheinerd B., Leyh C. et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from a international multicenter real-life cohort. Liver Cancer 2021;10:360–9.
56. Tovoli F., Dadduzio V., De Lorenzo S. et al. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Liver Cancer 2021;10:370–9.
57. Yoo C., Kim J.H., Ryu M.H. et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer 2021;10:107–14.
58. Bang Y.H., Lee C., Yoo C. et al. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:1–12.
59. Ho W.J., Zhu Q., Durham J. et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer 2021;2(9):891–903. DOI:10.1038/s43018-021-00234-4
60. Yau T., Zagonel V., Santoro A. et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 2020;38(4 Suppl):478.
61. Exelixis, Ipsen. Exelixis and Ipsen announce cabozantinib in combination with an immune checkpoint inhibitor significantly improved progression-free survival in phase 3 COSMIC-312 pivotal trial in patients with previously untreated advanced liver cancer. 2021.
62. Kim H.D., Bang Y., Lee M.A. et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int 2020;40(10):2544–52.
63. Rimassa L., Kelley R.K., Meyer T. et al. Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v257–8. DOI:10.1093/annonc/mdz247.006
64. Rodríguez-Hernández M.A., Chapresto-Garzón R., Cadenas M. et al. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell Death Dis 2020;11:339.
65. Esteban-Fabró R., Willoughby C.E., Piqué-Gili M. et al. Cabozantinib enhances Anti-PD1 activity and elicits a neutrophilbased immune response in hepatocellular carcinoma. Clin Cancer Res 2022;28(11):2449–60. DOI:10.1158/1078-0432.CCR-21-2517
66. Shlomai A., Leshno M., Goldstein D.A. Cabozantinib for patients with advanced hepatocellular carcinoma: a costeffectiveness analysis. Ther Adv Gastroenterol 2019;12:1–8. DOI:10.1177/1756284819878304
67. Sieg M., Hartmann M., Settmacher U., Arefian H. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. BMC Gastroenterol 2020;20:120.
68. Liao W., Huang J., Hutton D. et al. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liver Int 2019;00:1–9.
Рецензия
Просмотров:
270
Послать статью по эл. почте 